Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | E7107 + GSK3203591 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
E7107 | E 7107|E-7107 | E7107 is a derivative of Pladienolide D, which inhibits assembly of the spliceosome specifically by binding to SF3B1, thereby inhibiting splicing of pre-mRNA and cell-cycle progression (PMID: 27622333, PMID: 31558432). | ||
GSK3203591 | GSK591|EPZ015866 | PRMT5 Inhibitor 9 | GSK3203591 inhibits PRMT5, potentially resulting in decreased tumor cell growth (PMID: 29946150). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A - MLLT3 | acute myeloid leukemia | sensitive | E7107 + GSK3203591 | Preclinical - Cell culture | Actionable | In a preclinical study, E7107 and GSK3203591 synergistically inhibited survival of murine KMT2A-MLLT3 (reported as MLL-AF9)-driven acute myeloid leukemia cells in culture, regardless of SRSF2 mutation status (PMID: 31408619). | 31408619 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|